Gi-Young Sohn
Chief Executive Officer bij ENZYCHEM LIFESCIENCES CORPORATION
Vermogen: 6 M $ op 31-03-2024
Profiel
Gi-Young Sohn is currently the Chief Executive Officer & Director at ENZYCHEM LIFESCIENCES Corp.
since 2012.
He is also the Chairman at Bridget Lifesciences Corp.
since 2003.
Mr. Sohn has an undergraduate and graduate degree from Korea University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 18-04-2024 | 4 069 430 ( 4.78% ) | 6 M $ | 31-03-2024 |
Actieve functies van Gi-Young Sohn
| Bedrijven | Functie | Begin |
|---|---|---|
| ENZYCHEM LIFESCIENCES CORPORATION | Chief Executive Officer | 01-06-2012 |
Bridget Lifesciences Corp.
 Bridget Lifesciences Corp. Financial ConglomeratesFinance Bridget Lifesciences Corp. functions as an investment holding South Korean company. Hye-Kyung Kim has been the CEO of the private company since 2003. | Chairman | 01-01-2003 |
Opleiding van Gi-Young Sohn
| Korea University | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ENZYCHEM LIFESCIENCES CORPORATION | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Bridget Lifesciences Corp.
Bridget Lifesciences Corp. Financial ConglomeratesFinance Bridget Lifesciences Corp. functions as an investment holding South Korean company. Hye-Kyung Kim has been the CEO of the private company since 2003. | Finance |
